Table 2.

Clinical characteristics and mutation category in ovarian carcinoma patients

CharacteristicsBRCA1BRCA2Other HRRWT
N1487881888
Disease site
 Ovary131 (88.5%)65 (83.3%)68 (85.2%)734 (82.7%)
 Peritoneal16 (10.8%)12 (15.4%)12 (14.8%)131 (14.8%)
 Fallopian tube1 (0.7%)1 (1.3%)1 (1.2%)23 (2.6%)
Stage
 III/Optimal59 (39.9%)26 (33.3%)37 (45.7%)343 (38.6%)
 III/Suboptimal58 (39.2%)29 (37.2%)25 (30.9%)341 (38.4%)
 IV31 (20.9%)23 (29.5%)19 (23.5%)204 (23.0%)
Histology
 HG Serous127 (85.8%)70 (89.7%)65 (80.2%)709 (79.8%)
 LG Serousa4 (2.7%)01 (1.2%)41 (4.6%)
 Carcinoma, NS12 (8.1%)6 (7.7%)4 (12.6%)79 (8.9%)
 Endometrioid3 (2.0%)1 (1.3%)6 (7.4%)32 (3.6%)
 Clear cell2 (1.4%)1 (1.3%)3 (3.7%)22 (2.5%)
 Mucinous002 (2.5%)5 (0.6%)
Treatment
 CT + P → P53 (35.8%)28 (35.9%)27 (33.3%)300 (33.8%)
 CT + B → P34 (23.0%)19 (24.4%)26 (32.1%)307 (34.6%)
 CT + B → B61 (41.2%)31 (38.3%)28 (34.6%)281 (31.6%)
  • NOTE: Other HRR (other homologous recombination repair) refers to those with mutations in non-BRCA genes, including ATM, ATR, BARD1, BLM, BRIP1, CHEK2, MRE11A, NBN, PALB2, RAD51C, RAD51D, RBBP8, SLX4, and XRCC2.

  • Abbreviations: HG, high-grade, grades 2 and 3; LG, low-grade, grade 1; NS, not specified; CT, chemotherapy; P, placebo; B, bevacizumab.

  • aLow-grade serous carcinoma had a significantly lower total mutation rate when compared with high-grade serous carcinoma. P = 0.02, Fisher exact.